Clicky

Roche Holding AG(ROG)

Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.


Keywords: Medicine Pharmaceutical Cancer Pharmaceutical Products Disease Diabetes Immunology Neuroscience Hepatitis Transplantation Anemia Inflammatory Bowel Disease Hemophilia Inflammatory Treatment Of Inflammatory Bowel Disease Gastrointestinal Tract Disorders

Home Page: www.roche.com

Konzern Hauptsitz
Basel, 4070
Switzerland
Phone: 41 61 688 11 11


Officers

Name Title
Dr. Severin Schwan Ph.D. CEO & Exec. Director
Dr. Alan Hippe Chief Financial & Information Officer
Ms. Cristina A. Wilbur Chief People Officer
Dr. Johannes Carolus Clevers M.D., Ph.D. Head of Roche Pharma Research & Early Devel.
Dr. Thomas Schinecker Chief Exec. Officer of Roche Diagnostics
Mr. William N. Anderson Chief Exec. Officer of Roche Pharmaceuticals
Dr. Bruno Eschli Head of Investor Relations
Ms. Claudia Bockstiegel Gen. Counsel
Ms. Pascale Schmidt Chief Compliance Officer
Ms. Barbara Schadler Head of Group Communications

Exchange: SW

Country: CH

Currency: Swiss Franc (CHF)

Forward PE: 14.2045
Trailing PE: 16.4895
Price-to-Book MRQ: 9.6286
Price-to-Sales TTM: 3.7259
IPO Date:
Fiscal Year End: December
Full Time Employees: 100920
Back to stocks